Strain Shirota Enhances the In Vitro Antiproliferative Effect of Geniposide in Human Oral Squamous Carcinoma HSC-3 Cells
Overview
Affiliations
This study investigated the enhanced antiproliferative effect of strain Shirota (LcS) on geniposide actions in human oral squamous carcinoma HSC-3 cells. An MTT assay, flow cytometry, qPCR assay, western blot and HPLC were used for this study. The concentration of 1.0 × 10⁶ CFU/mL of LcS had no effect on the HOK normal oral epithelial cells and HSC-3 cancer cells. The 25 and 50 µg/mL geniposide concentrations also had no impact on HOK normal oral epithelial cells, but they had remarkable inhibitory effects on the growth of HSC-3 cancer cells, which are enhanced in the presence of LcS. By the flow cytometry assay, the LcS-geniposide-H (1.0 × 10⁶ CFU/mL LcS and 50 µg/mL geniposide)-treated HSC-3 cancer cells had the largest number of cells undergoing apoptosis compared to cells treated with other combinationsand obviously more than cells treated with only geniposide-H (50 µg/mL geniposide). Geniposide-H could increase the mRNA and protein expressions of caspase-3, caspase-8, caspase-9, Bax, p53, p21, IκB-α, Fas, FasL, TIMP-1, and TIMP-2 as well as decrease those of Bcl-2, Bcl-xL, HIAP-1, HIAP-2, NF-κB, COX-2, iNOS, MMP-2, and MMP-9 compared to other groups of cells, and LcS further enhanced these changes, with results that are greater than for the cells treated with only a high concentration of geniposide. The results of this study show thatLcS enhanced the antiproliferative effect of geniposide in HSC-3 cancer cells.
Shakya S, Danshiitsoodol N, Noda M, Sugiyama M Biosci Microbiota Food Health. 2024; 43(2):120-127.
PMID: 38562546 PMC: 10981940. DOI: 10.12938/bmfh.2023-066.
Liu F, Ma L, Chen W, Wang S, Wei C, Huang C BMC Microbiol. 2023; 23(1):293.
PMID: 37845623 PMC: 10580535. DOI: 10.1186/s12866-023-03050-1.
Mucin Binding Protein of Inhibits HT-29 Colorectal Cancer Cell Proliferation.
Ju X, Wu X, Chen Y, Cui S, Cai Z, Zhao L Nutrients. 2023; 15(10).
PMID: 37242197 PMC: 10223879. DOI: 10.3390/nu15102314.
Iridoid Derivatives as Anticancer Agents: An Updated Review from 1970-2022.
Ndongwe T, Witika B, Mncwangi N, Poka M, Skosana P, Demana P Cancers (Basel). 2023; 15(3).
PMID: 36765728 PMC: 9913650. DOI: 10.3390/cancers15030770.
Bai G, Chen B, Xiao X, Li Y, Liu X, Zhao D Exp Ther Med. 2022; 24(6):706.
PMID: 36382092 PMC: 9634504. DOI: 10.3892/etm.2022.11642.